AC Immune (ACIU) Receivables (2014 - 2026)

AC Immune (ACIU) has reported Receivables for 10 consecutive years, with $1.3 million the latest figure, recorded in Q4 2024.

• In Q4 2024, Receivables fell 99.99% year-over-year to $1.3 million; the TTM figure through Dec 2024 stood at $1.3 million (down 99.99% YoY), while the FY2024 annual figure was $1.3 million, down 99.99% from the prior year.
• Receivables fell to $1.3 million in Q4 2024 per ACIU's latest filing, from $29.4 million in the prior quarter.
• Across five years, Receivables topped out at $16.7 billion in Q4 2023 and bottomed at $1.3 million in Q4 2024.
• Historically, Receivables has averaged $2.5 billion across 4 years, with a median of $62.6 million in 2020.
• Annual changes were most pronounced in 2021 — Receivables surged 610.64% — and 2024, when it plunged 99.99%.
• AC Immune's Receivables stood at $66.4 million in 2020, then soared by 610.64% to $471.6 million in 2021, then soared by 3437.7% to $16.7 billion in 2023, then slumped by 99.99% to $1.3 million in 2024.
• Business Quant data shows ACIU's Receivables at $1.3 million in Q4 2024, $29.4 million in Q3 2024, and $1.3 million in Q2 2024.